Primary Bone Cancer Threat in Newly Identified Patients

Journal of Cancer Clinical Trials

ISSN: 2577-0535

Open Access

Commentary - (2022) Volume 7, Issue 5

Primary Bone Cancer Threat in Newly Identified Patients

Francesco Dalton*
*Correspondence: Francesco Dalton, Cancer Medicine Clinic, Lombardy, Italy, Email:
Cancer Medicine Clinic, Lombardy, Italy

Received: 10-May-2022, Manuscript No. jcct-22-64013; Editor assigned: 11-May-2022, Pre QC No. P-64013; Reviewed: 26-May-2022, QC No. Q-64013; Revised: 26-May-2022, Manuscript No. R-64013; Published: 30-May-2022 , DOI: 10.37421/2577-0535.2022.7.162
Citation: Dalton, Francesco. “Primary Bone Cancer Threat in Newly Identified Patients.” J Cancer Clin Trials 7 (2022): 162.
Copyright: © 2022 Dalton F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Li-Fraumeni syndrome and hereditary retinoblastoma are two rare genetic diseases that enhance the risk of bone cancer in families. Paget's disease is a bone disease. Paget's disease of the bone, which is most frequent in elderly persons, can raise the risk of developing bone cancer later in life. The most frequent type of bone cancer is osteosarcoma. The malignant cells in this tumour generate bone. The bones of the leg or arm are the most commonly affected by this type of bone cancer in children and young people. Osteosarcomas can develop outside of bones in rare cases [1].

The second most frequent type of bone cancer is chondrosarcoma. The malignant cells in this tumour create cartilage. In middle-aged and older adults, chondrosarcoma commonly develops in the pelvis, legs, or arms. Children who have familial retinoblastoma, a type of eye cancer, are more likely to acquire osteosarcoma. People with a family history of sarcoma, such as those with Li-Fraumeni syndrome, are at an increased risk of developing osteosarcoma. Researchers are discovering genes passed down through generations that put people at a higher risk of acquiring osteosarcoma than the general population. All of these conditions are extremely uncommon.

Any factor that increases your chances of contracting an illness such as cancer is referred to as a risk factor. The risk factor for various malignancies varies. Some risk factors, such as smoking, are modifiable. Others, such as a person's age or family history, are irreversible. However, just because you have a risk factor, or even numerous risk factors, does not indicate you will develop the disease. Many people who have one or more risk factors never develop cancer, whereas others who do develop cancer have few or no recognised risk factors. Primary bone malignancies (cancers that begin in the bones) come in a variety of forms, and while they share some characteristics, they do not all have the same risk factors [2].

People who have had radiation therapy for other reasons are more likely to develop bone sarcoma at the radiation therapy location. Radiation-related bone sarcomas can arise many years, if not decades, after treatment, so it's a good idea to keep an eye out for any new symptoms in an area that was previously treated with radiation, even if you're an adult who was treated as a child. Angiosarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) of soft tissue, and osteosarcoma are the most common sarcomas induced by radiation therapy, but other kinds can also develop. Early detection increases the chances of a successful treatment, thus those with known risk factors should see their doctor on a frequent basis to review their personal risk of developing bone sarcoma. This includes people with Li-Fraumeni syndrome, retinoblastoma, and other inherited sarcoma risk factors. For more information about your personal cancer risk, speak with your health-care team. Despite this, the majority of bone sarcomas develop in patients who have no identified risk factors [3-5].

Conflict of Interest



  1. Norris, Colleen M., Cindy Y.Y. Yip, Kara A. Nerenberg and Marie‐Annick Clavel, et al. "State of the science in women's cardiovascular disease: a Canadian perspective on the influence of sex and gender." J Am Heart Assoc 9 (2020): e015634.
  2. Google Scholar, Crossref, Indexed at

  3. Sanghavi, Monika, and Jourdan E. Triebwasser. "Women’s cardiovascular health: Selecting the best contraception." Med Clin 106 (2022): 365-376.
  4. Google Scholar, Crossref, Indexed at

  5. Abouzeid, Christiane, Deep Bhatt, and Nivee Amin. "The top five women’s health issues in preventive cardiology." Curr Cardiovasc Risk Rep 12 (2018): 1-9.
  6. Google Scholar, Crossref, Indexed at

  7. Shiu, Delaney. "Study of women's cardiovascular public health initiatives and program evaluation." PhD diss., 2021.
  8. Google Scholar, Crossref, Indexed at

  9. Ordovas, Karen G. "Invited Commentary: Enhancing skills for imaging diagnosis of spontaneous coronary artery dissection and other women’s cardiovascular diseases." RadioGraphics 41 (2021): E200-E201.
  10. Google Scholar, Crossref, Indexed at

Google Scholar citation report
Citations: 95

Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report

Journal of Cancer Clinical Trials peer review process verified at publons

Indexed In

arrow_upward arrow_upward